-
1
-
-
12444272739
-
Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: Focus on lipidregulating therapy
-
Woodman RJ, Chew GT, Watts GF. Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipidregulating therapy. Drugs. 2005;65:31-74.
-
(2005)
Drugs
, vol.65
, pp. 31-74
-
-
Woodman, R.J.1
Chew, G.T.2
Watts, G.F.3
-
2
-
-
56849101712
-
The importance of endothelin-1 for microvascular dysfunction in diabetes
-
Kalani M. The importance of endothelin-1 for microvascular dysfunction in diabetes. Vasc Health Risk Manag. 2008;4:1061-1068.
-
(2008)
Vasc Health Risk Manag
, vol.4
, pp. 1061-1068
-
-
Kalani, M.1
-
3
-
-
64749088854
-
Fibrates and microvascular complications in diabetes-insight from the FIELD study
-
Ansquer JC, Foucher C, Aubonnet P, Le Malicot K. Fibrates and microvascular complications in diabetes-insight from the FIELD study. Curr Pharm Des. 2009;15:537-552.
-
(2009)
Curr Pharm des
, vol.15
, pp. 537-552
-
-
Ansquer, J.C.1
Foucher, C.2
Aubonnet, P.3
Le Malicot, K.4
-
4
-
-
80052048877
-
Prevention of microvascular diabetic complications by fenofibrate: Lessons from FIELD and ACCORD
-
Hermans MP. Prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD. Diab Vasc Dis Res. 2011;8:180-189.
-
(2011)
Diab Vasc Dis Res
, vol.8
, pp. 180-189
-
-
Hermans, M.P.1
-
5
-
-
77954654472
-
Effects of medical therapies on retinopathy progression in type 2 diabetes
-
Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC, Jr., Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233-244.
-
(2010)
N Engl J Med
, vol.363
, pp. 233-244
-
-
Chew, E.Y.1
Ambrosius, W.T.2
Davis, M.D.3
Danis, R.P.4
Gangaputra, S.5
Greven, C.M.6
Hubbard, L.7
Esser, B.A.8
Lovato, J.F.9
Perdue, L.H.10
Goff Jr., D.C.11
Cushman, W.C.12
Ginsberg, H.N.13
Elam, M.B.14
Genuth, S.15
Gerstein, H.C.16
Schubart, U.17
Fine, L.J.18
-
6
-
-
33644652183
-
Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis
-
Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest. 2006;116:571-580.
-
(2006)
J Clin Invest
, vol.116
, pp. 571-580
-
-
Lefebvre, P.1
Chinetti, G.2
Fruchart, J.C.3
Staels, B.4
-
7
-
-
50649089597
-
Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease
-
Staels B, Maes M, Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2008;5:542-553.
-
(2008)
Nat Clin Pract Cardiovasc Med
, vol.5
, pp. 542-553
-
-
Staels, B.1
Maes, M.2
Zambon, A.3
-
8
-
-
0032565868
-
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators
-
Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 1998;393:790-793.
-
(1998)
Nature
, vol.393
, pp. 790-793
-
-
Staels, B.1
Koenig, W.2
Habib, A.3
Merval, R.4
Lebret, M.5
Torra, I.P.6
Delerive, P.7
Fadel, A.8
Chinetti, G.9
Fruchart, J.C.10
Najib, J.11
MacLouf, J.12
Tedgui, A.13
-
9
-
-
1842475911
-
Regulation of endothelial nitric oxide synthase by PPAR agonists: Molecular and clinical perspectives
-
Watts GF, Staels B. Regulation of endothelial nitric oxide synthase by PPAR agonists: molecular and clinical perspectives. Arterioscler Thromb Vasc Biol. 2004;24:619-621.
-
(2004)
Arterioscler Thromb Vasc Biol
, vol.24
, pp. 619-621
-
-
Watts, G.F.1
Staels, B.2
-
10
-
-
11144355198
-
Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells
-
Goya K, Sumitani S, Xu X, Kitamura T, Yamamoto H, Kurebayashi S, Saito H, Kouhara H, Kasayama S, Kawase I. Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2004;24:658-663.
-
(2004)
Arterioscler Thromb Vasc Biol
, vol.24
, pp. 658-663
-
-
Goya, K.1
Sumitani, S.2
Xu, X.3
Kitamura, T.4
Yamamoto, H.5
Kurebayashi, S.6
Saito, H.7
Kouhara, H.8
Kasayama, S.9
Kawase, I.10
-
11
-
-
0033527569
-
Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1
-
Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem. 1999;274:32048-32054.
-
(1999)
J Biol Chem
, vol.274
, pp. 32048-32054
-
-
Delerive, P.1
De Bosscher, K.2
Besnard, S.3
Vanden Berghe, W.4
Peters, J.M.5
Gonzalez, F.J.6
Fruchart, J.C.7
Tedgui, A.8
Haegeman, G.9
Staels, B.10
-
12
-
-
0036841258
-
Elevated plasma endothelin-1 levels in diabetes mellitus
-
Schneider JG, Tilly N, Hierl T, Sommer U, Hamann A, Dugi K, Leidig-Bruckner G, Kasperk C. Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens. 2002;15:967-972.
-
(2002)
Am J Hypertens
, vol.15
, pp. 967-972
-
-
Schneider, J.G.1
Tilly, N.2
Hierl, T.3
Sommer, U.4
Hamann, A.5
Dugi, K.6
Leidig-Bruckner, G.7
Kasperk, C.8
-
13
-
-
34547483404
-
TGF-beta1 and TSC-22 gene polymorphisms and susceptibility to microvascular complications in type 2 diabetes
-
Buraczynska M, Baranowicz-Gaszczyk I, Borowicz E, Ksiazek A. TGF-beta1 and TSC-22 gene polymorphisms and susceptibility to microvascular complications in type 2 diabetes. Nephron Physiol. 2007;106:p69-p75.
-
(2007)
Nephron Physiol
, vol.106
-
-
Buraczynska, M.1
Baranowicz-Gaszczyk, I.2
Borowicz, E.3
Ksiazek, A.4
-
14
-
-
0038801663
-
Functional cooperation between Smad proteins and activator protein-1 regulates transforming growth factor-beta-mediated induction of endothelin-1 expression
-
Rodríguez-Pascual F, Redondo-Horcajo M, Lamas S. Functional cooperation between Smad proteins and activator protein-1 regulates transforming growth factor-beta-mediated induction of endothelin-1 expression. Circ Res. 2003;92:1288-1295.
-
(2003)
Circ Res
, vol.92
, pp. 1288-1295
-
-
Rodríguez-Pascual, F.1
Redondo-Horcajo, M.2
Lamas, S.3
-
15
-
-
0035694910
-
Smad regulation in TGFbeta signal transduction
-
Moustakas A, Souchelnytskyi S, Heldin CH. Smad regulation in TGFbeta signal transduction. J Cell Sci. 2001;114(Pt 24):4359-4369.
-
(2001)
J Cell Sci
, vol.114
, Issue.PART 24
, pp. 4359-4369
-
-
Moustakas, A.1
Souchelnytskyi, S.2
Heldin, C.H.3
-
16
-
-
24944497786
-
Non-Smad TGF-beta signals
-
Moustakas A, Heldin CH. Non-Smad TGF-beta signals. J Cell Sci. 2005;118(Pt 16):3573-3584.
-
(2005)
J Cell Sci
, vol.118
, Issue.PART 16
, pp. 3573-3584
-
-
Moustakas, A.1
Heldin, C.H.2
-
17
-
-
45949086682
-
TGFbeta regulated gene expression by Smads and Sp1/KLF-like transcription factors in cancer
-
Ellenrieder V. TGFbeta regulated gene expression by Smads and Sp1/KLF-like transcription factors in cancer. Anticancer Res. 2008;28(3A):1531-1539.
-
(2008)
Anticancer Res
, vol.28
, Issue.3 A
, pp. 1531-1539
-
-
Ellenrieder, V.1
-
18
-
-
33845296149
-
The tumor suppressor KLF11 mediates a novel mechanism in transforming growth factor beta-induced growth inhibition that is inactivated in pancreatic cancer
-
Buck A, Buchholz M, Wagner M, Adler G, Gress T, Ellenrieder V. The tumor suppressor KLF11 mediates a novel mechanism in transforming growth factor beta-induced growth inhibition that is inactivated in pancreatic cancer. Mol Cancer Res. 2006;4:861-872.
-
(2006)
Mol Cancer Res
, vol.4
, pp. 861-872
-
-
Buck, A.1
Buchholz, M.2
Wagner, M.3
Adler, G.4
Gress, T.5
Ellenrieder, V.6
-
19
-
-
38149054804
-
Axin and GSK3-control Smad3 protein stability and modulate TGF-signaling
-
Guo X, Ramirez A, Waddell DS, Li Z, Liu X, Wang XF. Axin and GSK3-control Smad3 protein stability and modulate TGF-signaling. Genes Dev. 2008;22:106-120.
-
(2008)
Genes Dev
, vol.22
, pp. 106-120
-
-
Guo, X.1
Ramirez, A.2
Waddell, D.S.3
Li, Z.4
Liu, X.5
Wang, X.F.6
-
20
-
-
65649084845
-
Transforming growth factor-{beta}-inducible phosphorylation of Smad3
-
Wang G, Matsuura I, He D, Liu F. Transforming growth factor-{beta}- inducible phosphorylation of Smad3. J Biol Chem. 2009;284:9663-9673.
-
(2009)
J Biol Chem
, vol.284
, pp. 9663-9673
-
-
Wang, G.1
Matsuura, I.2
He, D.3
Liu, F.4
-
21
-
-
0037383322
-
GSK-3: Tricks of the trade for a multi-tasking kinase
-
Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci. 2003;116(Pt 7):1175-1186.
-
(2003)
J Cell Sci
, vol.116
, Issue.PART 7
, pp. 1175-1186
-
-
Doble, B.W.1
Woodgett, J.R.2
-
23
-
-
0036890093
-
Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus
-
Playford DA, Watts GF, Best JD, Burke V. Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. Am J Cardiol. 2002;90:1254-1257.
-
(2002)
Am J Cardiol
, vol.90
, pp. 1254-1257
-
-
Playford, D.A.1
Watts, G.F.2
Best, J.D.3
Burke, V.4
-
24
-
-
0026677532
-
HMEC-1: Establishment of an immortalized human microvascular endothelial cell line
-
Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC, Lawley TJ. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol. 1992;99:683-690.
-
(1992)
J Invest Dermatol
, vol.99
, pp. 683-690
-
-
Ades, E.W.1
Candal, F.J.2
Swerlick, R.A.3
George, V.G.4
Summers, S.5
Bosse, D.C.6
Lawley, T.J.7
-
25
-
-
0033520304
-
Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway
-
Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, Duriez P, Staels B. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res. 1999;85:394-402.
-
(1999)
Circ Res
, vol.85
, pp. 394-402
-
-
Delerive, P.1
Martin-Nizard, F.2
Chinetti, G.3
Trottein, F.4
Fruchart, J.C.5
Najib, J.6
Duriez, P.7
Staels, B.8
-
26
-
-
78149481592
-
Mammalian Krüppel-like factors in health and diseases
-
McConnell BB, Yang VW. Mammalian Krüppel-like factors in health and diseases. Physiol Rev. 2010;90:1337-1381.
-
(2010)
Physiol Rev
, vol.90
, pp. 1337-1381
-
-
McConnell, B.B.1
Yang, V.W.2
-
27
-
-
69449086702
-
Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human
-
Rakhshandehroo M, Hooiveld G, Müller M, Kersten S. Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS ONE. 2009;4:e6796.
-
(2009)
PLoS ONE
, vol.4
-
-
Rakhshandehroo, M.1
Hooiveld, G.2
Müller, M.3
Kersten, S.4
-
28
-
-
4143069155
-
KLF11 mediates a critical mechanism in TGF-beta signaling that is inactivated by Erk-MAPK in pancreatic cancer cells
-
Ellenrieder V, Buck A, Harth A, Jungert K, Buchholz M, Adler G, Urrutia R, Gress TM. KLF11 mediates a critical mechanism in TGF-beta signaling that is inactivated by Erk-MAPK in pancreatic cancer cells. Gastroenterology. 2004;127:607-620.
-
(2004)
Gastroenterology
, vol.127
, pp. 607-620
-
-
Ellenrieder, V.1
Buck, A.2
Harth, A.3
Jungert, K.4
Buchholz, M.5
Adler, G.6
Urrutia, R.7
Gress, T.M.8
-
29
-
-
0034603858
-
Roles for insulin receptor PI3-kinase and Akt in insulinsignaling pathways related to production of nitric oxide in human vascular endothelial cells
-
Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ. Roles for insulin receptor, PI3-kinase, and Akt in insulinsignaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000;101:1539-1545.
-
(2000)
Circulation
, vol.101
, pp. 1539-1545
-
-
Zeng, G.1
Nystrom, F.H.2
Ravichandran, L.V.3
Cong, L.N.4
Kirby, M.5
Mostowski, H.6
Quon, M.J.7
-
30
-
-
34248183465
-
Signaling by ALK5 mediates TGF-betainduced ET-1 expression in endothelial cells: A role for migration and proliferation
-
Castañares C, Redondo-Horcajo M, Magán-Marchal N, ten Dijke P, Lamas S, Rodríguez-Pascual F. Signaling by ALK5 mediates TGF-betainduced ET-1 expression in endothelial cells: a role for migration and proliferation. J Cell Sci. 2007;120(Pt 7):1256-1266.
-
(2007)
J Cell Sci
, vol.120
, Issue.PART 7
, pp. 1256-1266
-
-
Castañares, C.1
Redondo-Horcajo, M.2
Magán-Marchal, N.3
Ten Dijke, P.4
Lamas, S.5
Rodríguez-Pascual, F.6
-
31
-
-
0032557646
-
Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization of dominant-negative mutant of PKB
-
van Weeren PC, de Bruyn KM, de Vries-Smits AM, van Lint J, Burgering BM. Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization of dominant-negative mutant of PKB. J Biol Chem. 1998;273:13150-13156.
-
(1998)
J Biol Chem
, vol.273
, pp. 13150-13156
-
-
Van Weeren, P.C.1
De Bruyn, K.M.2
De Vries-Smits, A.M.3
Van Lint, J.4
Burgering, B.M.5
-
32
-
-
10744227563
-
Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway
-
Irukayama-Tomobe Y, Miyauchi T, Sakai S, Kasuya Y, Ogata T, Takanashi M, Iemitsu M, Sudo T, Goto K, Yamaguchi I. Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway. Circulation. 2004;109:904-910.
-
(2004)
Circulation
, vol.109
, pp. 904-910
-
-
Irukayama-Tomobe, Y.1
Miyauchi, T.2
Sakai, S.3
Kasuya, Y.4
Ogata, T.5
Takanashi, M.6
Iemitsu, M.7
Sudo, T.8
Goto, K.9
Yamaguchi, I.10
-
33
-
-
1942484870
-
Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway
-
Ogata T, Miyauchi T, Sakai S, Takanashi M, Irukayama-Tomobe Y, Yamaguchi I. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol. 2004;43:1481-1488.
-
(2004)
J Am Coll Cardiol
, vol.43
, pp. 1481-1488
-
-
Ogata, T.1
Miyauchi, T.2
Sakai, S.3
Takanashi, M.4
Irukayama-Tomobe, Y.5
Yamaguchi, I.6
-
34
-
-
49649117315
-
Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction
-
Chew GT, Watts GF, Davis TM, Stuckey BG, Beilin LJ, Thompson PL, Burke V, Currie PJ. Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction. Diabetes Care. 2008;31:1502-1509.
-
(2008)
Diabetes Care
, vol.31
, pp. 1502-1509
-
-
Chew, G.T.1
Watts, G.F.2
Davis, T.M.3
Stuckey, B.G.4
Beilin, L.J.5
Thompson, P.L.6
Burke, V.7
Currie, P.J.8
-
35
-
-
77954078831
-
Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients
-
Hamilton SJ, Chew GT, Davis TM, Watts GF. Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients. Clin Sci. 2010;118:607-615.
-
(2010)
Clin Sci
, vol.118
, pp. 607-615
-
-
Hamilton, S.J.1
Chew, G.T.2
Davis, T.M.3
Watts, G.F.4
-
36
-
-
28044452217
-
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial
-
FIELD Study Investigators
-
Keech A, Simes RJ, Barter P, et al.; FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-1861.
-
(2005)
Lancet
, vol.366
, pp. 1849-1861
-
-
Keech, A.1
Simes, R.J.2
Barter, P.3
-
37
-
-
36049001784
-
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial
-
FIELD Study Investigators
-
Keech AC, Mitchell P, Summanen PA, et al.; FIELD Study Investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370: 1687-1697.
-
(2007)
Lancet
, vol.370
, pp. 1687-1697
-
-
Keech, A.C.1
Mitchell, P.2
Summanen, P.A.3
-
38
-
-
80052048877
-
Non-invited review: Prevention of microvascular diabetic complications by fenofibrate: Lessons from FIELD and ACCORD
-
Hermans MP. Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD. Diab Vasc Dis Res. 2011;8:180-189.
-
(2011)
Diab Vasc Dis Res
, vol.8
, pp. 180-189
-
-
Hermans, M.P.1
-
39
-
-
65649142619
-
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): A prespecified analysis of a randomised controlled trial
-
FIELD Study Investigators
-
Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D'Emden MC, Laakso M, Baker JR, Keech AC; FIELD Study Investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet. 2009;373:1780-1788.
-
(2009)
Lancet
, vol.373
, pp. 1780-1788
-
-
Rajamani, K.1
Colman, P.G.2
Li, L.P.3
Best, J.D.4
Voysey, M.5
D'Emden, M.C.6
Laakso, M.7
Baker, J.R.8
Keech, A.C.9
-
41
-
-
0348226831
-
Diabetic nephropathy and transforming growth factor-beta: Transforming our view of glomerulosclerosis and fibrosis build-up
-
Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol. 2003;23:532-543.
-
(2003)
Semin Nephrol
, vol.23
, pp. 532-543
-
-
Chen, S.1
Jim, B.2
Ziyadeh, F.N.3
-
42
-
-
67650227476
-
The transforming growth factor-beta pathway is a common target of drugs that prevent experimental diabetic retinopathy
-
Gerhardinger C, Dagher Z, Sebastiani P, Park YS, Lorenzi M. The transforming growth factor-beta pathway is a common target of drugs that prevent experimental diabetic retinopathy. Diabetes. 2009;58:1659-1667.
-
(2009)
Diabetes
, vol.58
, pp. 1659-1667
-
-
Gerhardinger, C.1
Dagher, Z.2
Sebastiani, P.3
Park, Y.S.4
Lorenzi, M.5
|